Lorinda Simms
Nizam's Institute of Medical Sciences · 51 works · 6,919 citations · h-index 20
Top works
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
- The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
- Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
- Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios
- Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
- Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer
- PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial
- Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors
- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin
- Anti-tuberculous therapy for maintenance of remission in Crohn's disease
- Budesonide for maintenance of remission in Crohn's disease
- Lipid‐induced colonic hypersensitivity in irritable bowel syndrome: the role of 5‐HT3 receptors